Prognostic value of Systemic Immune-Inflammation Index in head and neck cancer

Engin Eren Kavak; İsmail Dilli; Ömer Bayır; Hüseyin Demirci; Samet Özlügedik

Makale detayları

Prognostic value of Systemic Immune-Inflammation Index in head and neck cancer

Yazarlar:

Engin Eren Kavak | İsmail Dilli | Ömer Bayır | Hüseyin Demirci | Samet Özlügedik

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji | Kemoterapi

Dergi:

Journal of Health Sciences and Medicine Vol.8 Issue 5, pp.747-753

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001358382

pISSN:

2636-8579

Anahtar kelimeler:

Özet:

 Aims: This study aimed to evaluate the prognostic value of the Systemic Immune-Inflammation Index SII in patients with head and neck cancer and its association with survival outcomes including disease-free survival DFS and overall survival OS. Methods: The patients diagnosed with head and neck cancer were retrospectively analyzed. Patients were stratified into two groups based on the SII cut-off value 796: low SII L-SII and high SII H-SII. Clinical, demographic, and treatment-related parameters were compared between the groups. Kaplan-Meier survival analysis and Cox regression were used for univariate and multivariate analyses of DFS and OS. Results: Of the total number of patients included in the study n184, 67 with high SII 796 exhibited significantly higher recurrence rates 43.3 vs. 8.5, p0.001 and higher mortality 26.9 vs. 11.1, p0.006 compared to those with low SII. Median DFS was shorter in the H-SII group 13.7 vs. 18.7 months, although the difference was not statistically significant p0.25. In multivariate Cox analysis, advanced stage HR: 3.00, 95 CI: 1.38-6.50, p0.005, ECOG 2 HR: 3.72, 95 CI: 1.35-10.22, p0.01, and high SII HR: 1.86, 95 CI: 1.01-3.16, p0.05 were independently associated with worse OS. Although high SII was not an independent predictor for DFS, it showed a clear trend toward worse outcomes HR: 1.56, 95 CI: 0.72-3.34, p0.25. Conclusion: High SII levels were associated with worse clinical outcomes and significantly higher rates of recurrence and mortality. While SII was an independent prognostic factor for OS, its effect on DFS did not reach statistical significance. These findings support the potential utility of SII as a simple, inflammation-based prognostic biomarker in head and neck cancers.

 Aims: This study aimed to evaluate the prognostic value of the Systemic Immune-Inflammation Index SII in patients with head and neck cancer and its association with survival outcomes including disease-free survival DFS and overall survival OS. Methods: The patients diagnosed with head and neck cancer were retrospectively analyzed. Patients were stratified into two groups based on the SII cut-off value 796: low SII L-SII and high SII H-SII. Clinical, demographic, and treatment-related parameters were compared between the groups. Kaplan-Meier survival analysis and Cox regression were used for univariate and multivariate analyses of DFS and OS. Results: Of the total number of patients included in the study n184, 67 with high SII 796 exhibited significantly higher recurrence rates 43.3 vs. 8.5, p0.001 and higher mortality 26.9 vs. 11.1, p0.006 compared to those with low SII. Median DFS was shorter in the H-SII group 13.7 vs. 18.7 months, although the difference was not statistically significant p0.25. In multivariate Cox analysis, advanced stage HR: 3.00, 95 CI: 1.38-6.50, p0.005, ECOG 2 HR: 3.72, 95 CI: 1.35-10.22, p0.01, and high SII HR: 1.86, 95 CI: 1.01-3.16, p0.05 were independently associated with worse OS. Although high SII was not an independent predictor for DFS, it showed a clear trend toward worse outcomes HR: 1.56, 95 CI: 0.72-3.34, p0.25. Conclusion: High SII levels were associated with worse clinical outcomes and significantly higher rates of recurrence and mortality. While SII was an independent prognostic factor for OS, its effect on DFS did not reach statistical significance. These findings support the potential utility of SII as a simple, inflammation-based prognostic biomarker in head and neck cancers.

 Aims: This study aimed to evaluate the prognostic value of the Systemic Immune-Inflammation Index SII in patients with head and neck cancer and its association with survival outcomes including disease-free survival DFS and overall survival OS. Methods: The patients diagnosed with head and neck cancer were retrospectively analyzed. Patients were stratified into two groups based on the SII cut-off value 796: low SII L-SII and high SII H-SII. Clinical, demographic, and treatment-related parameters were compared between the groups. Kaplan-Meier survival analysis and Cox regression were used for univariate and multivariate analyses of DFS and OS. Results: Of the total number of patients included in the study n184, 67 with high SII 796 exhibited significantly higher recurrence rates 43.3 vs. 8.5, p0.001 and higher mortality 26.9 vs. 11.1, p0.006 compared to those with low SII. Median DFS was shorter in the H-SII group 13.7 vs. 18.7 months, although the difference was not statistically significant p0.25. In multivariate Cox analysis, advanced stage HR: 3.00, 95 CI: 1.38-6.50, p0.005, ECOG 2 HR: 3.72, 95 CI: 1.35-10.22, p0.01, and high SII HR: 1.86, 95 CI: 1.01-3.16, p0.05 were independently associated with worse OS. Although high SII was not an independent predictor for DFS, it showed a clear trend toward worse outcomes HR: 1.56, 95 CI: 0.72-3.34, p0.25. Conclusion: High SII levels were associated with worse clinical outcomes and significantly higher rates of recurrence and mortality. While SII was an independent prognostic factor for OS, its effect on DFS did not reach statistical significance. These findings support the potential utility of SII as a simple, inflammation-based prognostic biomarker in head and neck cancers.

 Amaç: Bu çalışmada, baş ve boyun kanseri hastalarında Sistemik İmmün-İnflamasyon İndeksinin SII prognostik değeri ile hastalıksız sağkalım DFS ve genel sağkalım OS gibi sağkalım sonuçlarıyla olan ilişkisi değerlendirildi. Yöntem: Baş ve boyun kanseri tanısı almış hastalar retrospektif olarak analiz edildi. SII cut-off değeri olan 796ya göre hastalar düşük SII L-SII ve yüksek SII H-SII olmak üzere iki gruba ayrıldı. Gruplar arasında klinik, demografik ve tedaviye ilişkin parametreler karşılaştırıldı. DFS ve OS analizleri için Kaplan-Meier yöntemine dayalı sağkalım analizleri ve Cox regresyonu kullanılarak univaryant ve multivaryant analizler yapıldı. Bulgular: Toplam 184 hastanın yer aldığı çalışmada, yüksek SII grubundaki 796 67 hastada nüks oranı anlamlı olarak daha yüksek bulundu 43.3 vs. 8.5, p 0.001 ve ölüm oranı da belirgin şekilde fazlaydı 26.9 vs. 11.1, p  0.006. Medyan DFS, H-SII grubunda daha kısa olmasına rağmen 13.7 ay vs. 18.7 ay, bu fark istatistiksel olarak anlamlı değildi p0.25. Multivaryant Cox regresyon analizine göre, ileri evre HR: 3.00, 95 GA: 1.386.50, p0.005, ECOG 2 HR: 3.72, 95 GA: 1.3510.22, p0.01 ve yüksek SII HR: 1.86, 95 GA: 1.013.16, p0.05 bağımsız olarak daha kötü OS ile ilişkili bulundu. Yüksek SII, DFS için bağımsız bir belirleyici olmamakla birlikte, kötü prognoza eğilim gösterdi HR: 1.56, 95 GA: 0.723.34, p0.25. Sonuç: Yüksek SII düzeyleri, daha kötü klinik sonuçlar ile ve anlamlı düzeyde daha yüksek nüks ve mortalite oranları ile ilişkilendirildi. SII, OS açısından bağımsız bir prognostik faktör olarak saptanırken, DFS üzerindeki etkisi istatistiksel anlamlılığa ulaşmadı. Bu bulgular, SIInin potansiyel prognostik bir belirteç olarak kullanılabilirliğini desteklemektedir.

Makale detayları

Prognostic value of Systemic Immune-Inflammation Index in head and neck cancer

Yazarlar:

Engin Eren Kavak | İsmail Dilli | Ömer Bayır | Hüseyin Demirci | Samet Özlügedik

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji | Kemoterapi

Dergi:

Journal of Health Sciences and Medicine Vol.8 Issue 5, pp.747-753

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001358382

pISSN:

2636-8579

Head and neck cancer

Systemic Immune-Inflammation Index

overall survival

progression-free survival

disease-free survivalBaş ve boyun kanseri

Sistemik immün-inflamasyon indeksi

Genel sağkalım

Progresyonsuz sağkalım

Hastalıksız sağkalım

Sayı

Makale detayları

Yazarlar: Engin Eren Kavak | İsmail Dilli | Ömer Bayır | Hüseyin Demirci | Samet Özlügedik

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Klinik Onkoloji | Kemoterapi

Dergi: Journal of Health Sciences and Medicine Vol.8 Issue 5, pp.747-753

Belge Tipi: Makale

Yayın Tarihi: 9/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001358382

pISSN: 2636-8579

Sayı

Yazarlar:

Engin Eren Kavak | İsmail Dilli | Ömer Bayır | Hüseyin Demirci | Samet Özlügedik

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji | Kemoterapi

Dergi:

Journal of Health Sciences and Medicine Vol.8 Issue 5, pp.747-753

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001358382

pISSN:

2636-8579